Dimitri A. Breems

Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications

Correction: Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Correction: Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Journal: Bone marrow transplantation
Published: May 05, 2026

Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies.

Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies.

Journal: HemaSphere
Published: February 26, 2026

Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive Chemotherapy.

Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive Chemotherapy.

Journal: American journal of hematology
Published: January 29, 2026

Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Journal: Bone marrow transplantation
Published: October 20, 2025

Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Journal: Bone marrow transplantation
Published: October 20, 2025

Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy versus liposomal cytarabine and daunorubicin.

Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy versus liposomal cytarabine and daunorubicin.

Journal: Haematologica
Published: October 16, 2025

Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial.

Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial.

Journal: Leukemia
Published: June 09, 2025

Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients.

Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients.

Journal: British journal of haematology
Published: January 27, 2025

A revised prognostic model for patients with acute myeloid leukemia and first relapse.

A revised prognostic model for patients with acute myeloid leukemia and first relapse.

Journal: Blood advances
Published: January 06, 2025

Different features of acute myeloid leukemia stem cell quantification in intensively treated patients.

Different features of acute myeloid leukemia stem cell quantification in intensively treated patients.

Journal: Haematologica
Published: December 02, 2024

CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents.

CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents.

Journal: Leukemia
Published: November 09, 2024

Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.

Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.

Journal: Annals of hematology
Published: July 23, 2024
Showing 1-12 of 47

Last Updated: 09/26/2026